Immunization with both T cell-dependent and T cell-independent vaccines augments HIV viral load secondarily to stimulation of tumor necrosis factor α

AIDS Research and Human Retroviruses

Volumn 14, Issue 9, 1998, Pages 727-734

  Viganò, Alessandra ^a   Bricalli, Dorella ^a   Trabattoni, Daria ^a   Salvaggio, Antonino ^b   Ruzzante, Stefania ^a   Barbi, Maria ^c   Sanzo, Giuseppe D I ^a   Principi, Nicola ^a   Clerici, Mario ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Istituto di Virologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; DIDANOSINE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; PNEUMOCOCCUS VACCINE; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE;

ARTICLE; BACTERIAL CELL WALL; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; LONG TERMINAL REPEAT; LYMPHOCYTE COUNT; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD;

EID: 0032503529     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.727     Document Type: Article

References (35)

1. Bukrinsky MI, Stanwick TL, Dempsey MP, and Stevenson M: Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 1990;254:423-428.
2. Chun TW, Carruth L, Finzi D, et al.: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (London) 1997;387:183-188.
3. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, and Siliciano RF: In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency. Nature Med 1995;1:1284-1290.
4. Zagury D, Bernard J, and Leonard R: Long-term cultures of HTLV-III-infected T-cells: A model of cytopathology of T-cell depletion in AIDS. Science 1986;231:850-854.
5. Poli G and Fauci AS: The effect of cytokines and pharmacologic agents on chronic HIV infection. AIDS Res Hum Retroviruses 1992;8:191-202.
6. Rosenberg ZF and Fauci AS: Induction of expression of HIV in latently or chronically infected cells. AIDS Res Hum Retroviruses 1989;5:1-8.
7. Zack JA, Arrigo SJ, Weitsman SR, et al.: HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. Cell 1990;61:213-222.
8. Folks T, Kelly J, Benn S, et al.: Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. J Immunol 1986; 136:4049-4056.
9. Koyanagi Y, O'Brien WA, Zhao JQ, et al.: Cytokines alter production of HIV from primary mononuclear phagocytes. Science 1988;241:1637-1641.
10. Rich E, Chen IYS, Zack JA, Leonard ML, and O'Brien WA: Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus expression. J Clin Invest 1992;87:176-186.
11. Ho DD: HIV-1 viraemia and influenza. Lancet 1992;339: 1549-1551.
12. Janoff EM, Swindells S, Brichacek B, and Stevenson M: Increased HIV-1 burden with immune activation following immunization with pneumococcal vaccine. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 1995. p. 1248. [Abstract No. 1237]
13. O'Brien WA, Grovit-Ferbas K, Namaze A, et al.: Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995;3:1082-1090.
14. Brichacek B, Swindells S, Pirruccello S, et al.: Increase in HIV-1 replication following vaccination against opportunistic infections. In: 24th Annual Keystone Symposium on HIV Pathogenesis, Keystone, Colorado, 1995. p. 204. [Abstract No. D-4]
15. Staprans SI, Hamilton BL, Follansbee SE, et al.: Activation of virus replication after vaccination of HIV-1 infected individuals. J Exp Med 1995;182:1727-1736.
16. Stanley SK, Ostrowsky MA, Justement JS, et al.: Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996;334:1222-1230.
17. Brichacek B, Swindells S, Janoff EN, Pirruccello S, and Stevenson M: Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis 1996;174:1191-1199.
18. Mellors JW, Rinaldo CR Jr, Gupta P, et al.: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1171.
19. Balotta C, Colombo C, Colucci G, et al.: Plasma viremia and virus phenotype are correlates of disease progression in vertically human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 1997;16:205-212.
20. Parker DC: T-cell dependent B cell activation. Annu Rev Immunol 1993;11:331-354.
21. Vitetta ES, Fernandez-Botran R, Myers CD, and Sanders VM: Cellular interactions in the humoral response. Adv Immunol 1989; 45:1-54.
22. Centers for Disease Control: CDC classification system for human immunodeficiency virus (HIV) infection in children under 13 years of age. MMWR 1994;43(RR-12):1.
23. Clerici M, Hakim FT, Venzon DJ, et al.: Changes in interleukin 2 and interleukin 4 production in asymptomatic, HIV-seropositive individuals. J Clin Invest 1993;91:759-765.
24. Morrison DF: Multivariate Statistical Methods. McGraw-Hill, New York, 1978, pp. 153-216.
25. Yerly S, Wunderlich W, Wyler W, et al.: Influenza immunization of HIV-1 infected patients does not increase HIV-1 viral load. AIDS 1994;8:1503-1510.
26. Ramilo O, Hicks PJ, and Borvak J: T cell activation and human immunodeficiency virus replication after influenza immunization of infected children. Pediatr Infect Dis J 1996;15:197-202.
27. Jackson C, Vavro CL, Valentine ME, Pennington KN, Randall Lanier E, and Katz SL: Effect of influenza immunization on immunologic and virologic characteristics of pediatric patients infected with human immunodeficiency virus. Pediatr Infect Dis J 1997;16:200-206.
28. + lymphocytes counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-432.
29. Carpenter CCJ, Fischl MA, Hammer S, et al.: Antiretroviral therapy for HIV infection in 1996. JAMA 1996;276:146-150.
30. Tasker S, O'Brien JW, Rossetti R, et al.: Effects of influenza vaccination in HIV infected patients: A double-blinded, placebo-controlled trial. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 1995. p. 9. [Abstract LB-11]
31. Dalgleish AG, Beverly PC, Clapham PR, Crawford DH, Greaves MF, and Weiss RA: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (London) 1984;312:763-767.
32. Poland G, Love K, and Huges C: Routine immunization of the HIV-seropositive patient. J Gen Intern Med 1990;5:147-152.
33. Vykarnam A, McKeating J, Meager A, and Beverley PC: Tumor necrosis factor (α,β) induced by HIV-1 in peripheral blood mononuclear cells potentiates virus replication. AIDS 1990; 4:21-28.
34. Mellors JW, Griffith BP, Ortis MA, Landry ML, and Ryan JR: Tumor necrosis factor-α/cachectin enhances human immunodeficiency virus type 1 replication in primary macrophages. J Infect Dis 1991;163:78-84.
35. Duh EJ, Maury WJ, Folk TM, Fauci AS, and Rabson AB: Tumor necrosis factor a activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-κB site long terminal repeat. Proc Natl Acad Sci USA 1990;86:5974-5979.